TP53 and non-small cell lung carcinoma: Targeting the TIGAR may elucidate the mechanism by which the combined treatment of p53 and cisplatin increases the sensitivity of tumor cells from the perspective of the metabolism and apoptosis, and may provide a theoretical basis for the treatment of non-small-cell lung cancer.